Benfotiamine Is Vitamin B1 With a Fake ID. Your Small Intestine Waves It Right Through.

The Oasis Health Journal · Submitted July 20, 2026 · 11:20 AM ET

Vitamin B1 has a doorman. At the doses you get from food, thiamine enters your small intestine by active transport, which is a polite way of saying there is a limited number of carriers and they are all busy. Past a certain point those carriers saturate, and everything else has to get in by passive diffusion, which works about as well as it sounds.

So somebody built a workaround.

Benfotiamine is not vitamin B1. It is a synthetic molecule called S-benzoylthiamine O-monophosphate, which is B1 with a benzoyl group bolted on and a phosphate hanging off the side. It looks enough like thiamine to eventually become thiamine. It just does not use thiamine's door.

The trick, and it is a good one

Intestinal alkaline phosphatases snip the phosphate off at the brush border, converting benfotiamine into S-benzoylthiamine. That version is lipophilic, so it slips through cell membranes instead of standing in line, reaches the bloodstream, and turns back into ordinary thiamine inside your red blood cells and liver. The molecule that clocks in for work is plain B1. It just took the fire escape.

The numbers are not subtle. In a head-to-head pharmacokinetic study, plasma thiamine bioavailability from benfotiamine came in at roughly 1,147% of thiamine hydrochloride, with thiamine diphosphate (the active cofactor) in red blood cells at about 196%. Several times more thiamine circulating, roughly double the working form inside the cells.

The part on the label that is wrong

Benfotiamine is almost always sold as 'fat-soluble B1.' It is not. Researchers who actually tried to dissolve the stuff reported that benfotiamine is practically insoluble in water, in organic solvents, and in oil, which is an impressive refusal to cooperate with anyone. It is an amphiphilic S-acyl derivative, and it behaves differently from the genuinely lipid-soluble thiamine disulfides (allithiamine from garlic, plus synthetic sulbutiamine and fursultiamine).

Which matters, because destinations differ. In mice given oral benfotiamine, thiamine climbed quickly in blood and liver and did not move in the brain, even after 14 days of dosing. Sulbutiamine, the true lipid-soluble cousin, does get into the brain, which is why it acts like a central nervous system drug and benfotiamine does not. That is the cleanest explanation for why benfotiamine's track record lives out in the peripheral tissues.

Peripheral tissues is exactly where it was aimed

In 2008 the BENDIP trial randomized 165 people with symmetrical distal diabetic polyneuropathy to 600 mg of benfotiamine, 300 mg, or placebo. After six weeks the Neuropathy Symptom Score improved most in the 600 mg group and least in the placebo group (p = 0.033, per protocol population). Six weeks is a long weekend by nerve standards, but it was a real signal, and it kept the compound in the conversation for the better part of two decades.

Then somebody finally ran the long version.

The BOND study, published in 2026, gave people with type 2 diabetes and mild to moderate symptomatic polyneuropathy 300 mg of benfotiamine twice a day, or placebo, for twelve straight months. The primary endpoint was corneal nerve fiber length measured by corneal confocal microscopy, which sounds exotic until you learn the cornea is one of the few places you can photograph small nerve fibers without cutting anybody open.

It was well tolerated, and that is the good news. Corneal nerve fiber length did not differ significantly between groups. Neither did the other three corneal measures. Neither did the neurophysiological or clinical measures of neuropathy. The small increase in the benfotiamine arm landed far below the effect size the study was built to detect.

That is what a null result looks like when it is run properly, and it beats another six-week trial. A full year of clean safety data plus a clear miss on the hard endpoints tells you something specific: the compound is not doing what a lot of labels quietly imply it does.

The unresolved side plot

A phase IIa trial gave 600 mg of benfotiamine daily for a year to about 70 people with amyloid-confirmed mild cognitive impairment or mild Alzheimer's dementia. It missed its primary cognitive endpoint (the ADAS-Cog increase was 43% smaller than placebo, p = 0.125, which is the statistical version of almost). Worsening on the Clinical Dementia Rating scale was 77% lower, p = 0.034, and treatment was safe throughout. A larger trial called BenfoTeam is now running to settle it.

Which sits awkwardly next to the mouse data showing benfotiamine does not raise brain thiamine. Nobody has squared those two findings, and it would be dishonest to pretend the file is closed.

Some context on the dose

The Recommended Dietary Allowance for thiamine is 1.2 mg a day for adult men and 1.1 mg for adult women. These trials used 600 to 1,200 mg. That is not a vitamin dose wearing a vitamin's clothes, that is a pharmacological dose, and benfotiamine has carried prescription status in Germany since 1993 while sitting on the open supplement shelf here.

None of which makes thiamine unimportant. Depending on the study, somewhere between 17% and 79% of people with diabetes show poor thiamine status on erythrocyte transketolase testing, and up to 20% to 30% of older adults have lab indicators suggesting some degree of deficiency. Correcting an actual shortfall is a different job from expecting a megadose to rebuild damaged nerves, and correcting shortfalls is the job B1 is unambiguously good at.

Where that leaves the bottle

If you are looking at benfotiamine, the honest pitch is this: it raises thiamine and thiamine diphosphate far more reliably than plain vitamin B1 does, it has a year of controlled safety data behind it, and the disease-modifying claims did not survive a proper twelve-month test. Plenty of people take it as one piece of a broader B-complex approach, often alongside alpha lipoic acid, which has its own famously mixed record.

Whatever you land on, freshness is not a marketing word around here. We source professional-grade formulas per order instead of warehousing them until the potency quietly drifts. It ships slower. That is the trade, and we think it is the right one.

This article is for education only. It is not medical advice, and it is not a substitute for talking with your own clinician, particularly if you have diabetes or diagnosed neuropathy.

Sources

1. Effects of benfotiamine treatment over 12 months on morphometric, neurophysiological and clinical measures in type 2 diabetes patients with symptomatic polyneuropathy (BOND study), 2026
2. BOND study protocol: a randomised double-blind, placebo-controlled trial over 12 months, BMJ Open Diabetes Research and Care
3. Pharmacokinetic study of benfotiamine and the bioavailability assessment compared to thiamine hydrochloride, J Clin Pharmacol 2014
4. Benfotiamine, a synthetic S-acyl thiamine derivative, has different mechanisms of action than lipid-soluble thiamine disulfide derivatives, BMC Pharmacology
5. NIH Office of Dietary Supplements, Thiamin Fact Sheet for Health Professionals
6. Benfotiamine in Diabetic Polyneuropathy (BENDIP): a randomised, double blind, placebo-controlled study, Exp Clin Endocrinol Diabetes 2008
7. Benfotiamine and Cognitive Decline in Alzheimer's Disease: Results of a Randomized Placebo-Controlled Phase IIa Clinical Trial
8. Protocol for the BenfoTeam phase 2A-2B trial of benfotiamine in early Alzheimer's disease